KAMADA LTD
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Accelerated filer
State of Incorporation
Israel
Business Address
2 HOLTZMAN ST., SCIENCE PARK, REHOVOT, L3, 7670402
Mailing Address
2 HOLTZMAN ST., SCIENCE PARK, REHOVOT, L3, 7670402
Phone
97289406472
Fiscal Year End
1231
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
| 4 Insider stock transaction report | April 9, 2026 | View on SEC |
Annual Reports
20-F
March 11, 2026
- KAMADA LTD specializes in plasma-derived therapeutics, with clear descriptions of its core business, products, and strategic expansions.
- The company provides strong financial projections for 2026, building on its 2025 results and outlining key growth drivers.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.